What are the leading monoclonal antibody treatments for cancer?

The history of monoclonal antibody treatments for cancer

Cancer remains one of the world’s major health challenges. According to IARC/WHO data, around 20 million new cancer cases and 9.7 million cancer-related deaths were estimated worldwide in 2022. Lung, breast, colorectal, prostate, and stomach cancers remain among the most commonly diagnosed cancers globally.

Conventional chemotherapy has long been a cornerstone of cancer treatment, but its limited ability to distinguish between healthy and malignant cells often results in systemic toxicity and significant side effects. This has driven the development of more targeted therapeutic approaches.

Soon after the development of hybridoma technology in 1975, researchers recognized the potential of monoclonal antibodies as cancer therapeutics. Rituximab, approved by the FDA in 1997, was the first monoclonal antibody used in oncology. This chimeric anti-CD20 antibody transformed the treatment of B-cell non-Hodgkin lymphoma and marked the beginning of antibody-based targeted cancer therapy.

Growth targeting monoclonal antibody treatments for cancer

Monoclonal antibodies can inhibit tumor growth by blocking receptors or ligands involved in oncogenic signaling. One of the most established examples is the HER family, particularly HER2 and EGFR, which are involved in the growth and survival of several epithelial tumors.

Trastuzumab, a humanized IgG1 antibody targeting HER2, was approved for HER2-positive breast cancer and remains a foundational example of targeted antibody therapy. Cetuximab, a chimeric anti-EGFR antibody, is another key treatment used in colorectal and head and neck cancers.

Anti-angiogenic antibodies also play an important role in oncology. Bevacizumab targets VEGF-A and is used across several cancer types, while ramucirumab targets VEGFR2 and is used in indications including gastric cancer.

More recently, the concept of growth-targeting antibodies has expanded beyond “naked” monoclonal antibodies. Antibody-drug conjugates such as trastuzumab deruxtecan combine target specificity with cytotoxic payload delivery. In 2024, trastuzumab deruxtecan received FDA accelerated approval for unresectable or metastatic HER2-positive solid tumors, reflecting the increasing importance of antibody-based precision oncology.

Learn more about

antibody engineering services

Immune response modulators in monoclonal antibody treatments for cancer

Cancer cells can evade immune surveillance by exploiting inhibitory pathways known as immune checkpoints. Monoclonal antibodies targeting these checkpoints have become a major class of cancer immunotherapies.

Ipilimumab targets CTLA-4, while nivolumab and pembrolizumab target PD-1. These immune checkpoint inhibitors have changed the treatment landscape in several cancers, including melanoma, lung cancer, renal cell carcinoma, and other solid tumors.

The field continues to evolve, not only through new indications and combinations, but also through improved formulations. For example, the FDA approved subcutaneous nivolumab and hyaluronidase-nvhy in 2024 for use across approved adult solid tumor nivolumab indications, illustrating how established antibody therapies continue to be optimized for clinical use.

Beyond checkpoint inhibition, next-generation antibody formats are gaining momentum. Bispecific antibodies can redirect immune cells toward cancer cells by binding two different targets, while engineered antibodies can be optimized for affinity, Fc function, developability, or format conversion.

Explore antibody optimization services
Discover custom recombinant antibody production

Concluding remarks

Monoclonal antibodies were among the first targeted biologics to transform cancer treatment. Today, they remain central to oncology, from growth-factor blockade and anti-angiogenic therapy to immune checkpoint inhibition and advanced antibody formats.

The field is now moving toward increasingly sophisticated antibody-based therapeutics, including bispecific antibodies, ADCs, Fc-engineered antibodies, and optimized recombinant formats. This evolution makes antibody discovery, engineering, characterization, and production more critical than ever.

With technologies such as phage display services, AI-assisted antibody optimization, recombinant antibody production, and integrated therapeutic antibody development, researchers can accelerate the identification and development of promising candidates for oncology research.

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
   https://pubmed.ncbi.nlm.nih.gov/38572751/
2. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278-287.
   https://pubmed.ncbi.nlm.nih.gov/22437872/
3. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355.
   https://pubmed.ncbi.nlm.nih.gov/29567705/
4. Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the “high-hanging fruit”. Nat Rev Drug Discov. 2018;17(3):197-223.
   https://pubmed.ncbi.nlm.nih.gov/29192274/
5. Kaplon H, Crescioli S, Chenoweth A, et al. Antibodies to watch in 2023. mAbs. 2023;15(1):2153410.
   https://pubmed.ncbi.nlm.nih.gov/36520039/